...
首页> 外文期刊>Neuropharmacology >The binding orientation of epibatidine at alpha 7 nACh receptors
【24h】

The binding orientation of epibatidine at alpha 7 nACh receptors

机译:α7nach受体在α7nach受体在α的结合取向

获取原文
获取原文并翻译 | 示例
           

摘要

Epibatidine is an alkaloid toxin that binds with high affinity to nicotinic and muscarinic acetylcholine receptors, and has been extensively used as a research tool. To examine binding interactions at the nicotinic receptor, it has been co-crystallised with the structural homologue acetylcholine binding protein (AChBP; PDB ID 2BYQ), and with an AChBP chimaera (3SQ6) that shares 64% sequence identity with the alpha 7 nACh receptor. However, the binding orientations revealed by AChBP co-crystal structures may not precisely represent their receptor homologues and experimental evidence is needed to verify the ligand poses. Here we identify potential binding site interactions between epibatidine and AChBP residues, and substitute equivalent positions in the alpha 7 nACh receptor. The effects of these are probed by [H-3]epibatidine binding following the expression alpha 7 nACh receptor cysteine mutants in HEM 293 cells. Of the sixteen mutants created, the affinity of epibatidine was unaffected by the substitutions Q55C, L106C, L116C, T146C, D160C and S162C, reduced by C186A and C187A, increased by Q114C and S144C, and abolished by W53C, Y91C, N104C, W145C, Y184C and Y191C. These results are consistent with the predicted orientations in AChBP and suggest that epibatidine is likely to occupy a similar location at alpha 7 nACh receptors. We speculate that steric constraints placed upon the C-5 position of the pyridine ring in 3SQ6 may account for the relatively poor affinities of epibatidine derivatives that are substituted at this position. Crown Copyright (C) 2017 Published by Elsevier Ltd.
机译:表皮吲哚是一种生物碱毒素,其与烟碱和毒蕈碱乙酰胆碱受体的高亲和力结合,并且已被广泛地用作研究工具。为了检查烟碱受体的结合相互作用,它已经用结构同源物质乙酰胆碱结合蛋白(ACHBP; PDB ID 2byQ)和AchBP Chimaera(3SQ6)与α7Nach受体共享64%的序列同一性。然而,ACHBP共晶结构揭示的结合取向可能不精确地代表其受体同源物,并且需要实验证据来验证配体姿势。在这里,我们鉴定了表皮脒和ACHBP残基之间的潜在结合位点相互作用,并替代α7NACH受体中的等同位置。通过在下摆293细胞中表达α7Nach受体半胱氨酸突变体的[H-3]表达肽结合来探测这些效果。在产生的十六个突变体中,表皮嘌呤的亲和力不受Q55C,L106C,L116C,T146C,D160C和S162C的影响,由C114C和C187A减少,通过Q114C和S144C减少,并由W53C,Y91C,N104C,W145C(W145C)减少。 Y184C和Y191C。这些结果与ACHBP中的预测取向一致,表明EPIBATIDININ可能在α7NACH受体中占据相似的位置。我们推测3SQ6中吡啶环的C-5位放置的空间约束可以考虑在该位置取代的表皮脒衍生物的相对较差的亲和力。欧姆维尔有限公司发布的皇冠版权(c)2017

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号